To futility but not beyond as Infinity's Hedgehog becomes road kill
04:20 EDT 19 Jun 2012 | SCRIP
Infinity Pharmaceuticals said it was halting another Phase II trial of its lead candidate, saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, in patients with locally advanced, inoperable chondrosarcoma, a rare and.....
Original Article: To futility but not beyond as Infinity's Hedgehog becomes road kill
More From BioPortfolio on "To futility but not beyond as Infinity's Hedgehog becomes road kill"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
